141943-04-6

Basic information

• Product Name: 1-BENZYLPIPERIDINE-3-CARBOXYLIC ACID
• Synonyms: 1-BENZYLPIPERIDINE-3-CARBOXYLIC ACID;N-phenylmethyl-RS-3-Piperidinecarboxylic acid
• CAS NO: 141943-04-6
• Molecular Formula: C₁₃H₁₇NO₂
• Molecular Weight: 219.28
• Mol File: 141943-04-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 358.584°C at 760 mmHg
• Flash Point: 170.666°C
• Appearance: /
• Density: 1.165
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.572
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-BENZYLPIPERIDINE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYLPIPERIDINE-3-CARBOXYLIC ACID(141943-04-6)
• EPA Substance Registry System: 1-BENZYLPIPERIDINE-3-CARBOXYLIC ACID(141943-04-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 141943-04-6(Hazardous Substances Data)

Usage

General Description

1-Benzylpiperidine-3-carboxylic acid is a chemical compound with the molecular formula C16H21NO2. It is primarily used in the pharmaceutical industry as a precursor in the synthesis of various drugs, particularly those targeting the central nervous system. 1-BENZYLPIPERIDINE-3-CARBOXYLIC ACID is known for its potential as a building block in the creation of novel pharmaceutical agents. It is also used in medicinal chemistry research as a starting material for the development of new drugs with potential therapeutic applications. Additionally, the compound has been studied for its potential effects on the central nervous system and its potential use in the treatment of various neurological and psychiatric disorders.

InChI:InChI=1/C13H17NO2/c15-13(16)12-7-4-8-14(10-12)9-11-5-2-1-3-6-11/h1-3,5-6,12H,4,7-10H2,(H,15,16)

Upstream product

• 141943-03-5 N-benzylnipecotic acid benzyl ester 
• 72551-53-2 ethyl 1-benzylpiperidine-3-carboxylate 
• 100-44-7 benzyl chloride 
• 498-95-3 nipecotic acid 
• 100-39-0 benzyl bromide 
• 71962-74-8 Ethyl nipecotate 

Downstream Products

• 769907-38-2 1-benzyl-piperidine-3-carbonyl chloride 
• 149452-46-0 (4-fluorophenyl)piperidin-3-ylmethanone 
• 639468-28-3 3-(4-fluorobenzoyl)piperidine-1-carboxylic acid ethyl ester 
• 639468-31-8 3-(4-fluorobenzoyl)piperidine-1-carboxylic acid tert-butyl ester 
• 639468-33-0 3-[(4-fluorophenyl)hydroxymethyl]piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE and INFLAMMATORY DISEASES

The present invention relates to compounds of formula (I) that are inhibitors of PDElA, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation.

BENZAMIDE DERIVATIVES

A compound represented by formula (1): wherein X is a single bond or a substituted or unsubstituted lower alkylene group; Z is a saturated or unsaturated monocyclic hydrocarbon ring group or the like; and each of R1, R2, R3 and R4, which may be the same or different, is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug has inhibitory effect on Rho kinase and hence is useful for treating diseases which are such that morbidity due to them is expected to be improved by inhibition of Rho kinase and secondary effects such as inhibition of the Na+/H+ exchange transport system caused by the Rho kinase inhibition, for example, hypertension.

Syntheses and Binding Studies of New [(Aryl)(aryloxy)methyl]piperidine Derivatives and Related Compounds as Potential Antidepressant Drugs with High Affinity for Serotonin (5-HT) and Norepinephrine (NE) Transporters

In a wide search program toward new, efficient, and fast-acting antidepressant drugs, we have prepared series of new compounds having an (aryl)(aryloxy)methyl moiety linked directly or through a methylene chain to different substituted and unsubstituted cycles (isoquinoline, piperazine, piperidine, tetrahydropyran, or cyclopentane). These compounds have been evaluated for their affinities for serotonin (5-HT) transporter (SERT) and 5-HT1A and 5-HT2A receptors. Racemic mixtures of 4-[(aryl)(aryloxy)methyl]piperidine derivatives showed much higher affinity values for SERT than fluoxetine and resulted in lack of affinity for 5-HT 1A and 5-HT2A receptors. Some of these racemic mixtures were resolved to their enantiomers and tested for binding to norepinephrine (NE) transporter (NET), dopamine (DA) transporter (DAT), and α2 receptor. Several of these enantiomers [(-)-15b, (-)-15j, (-)-15t, (+)-15u] displayed a dual binding profile with affinities for SERT and NET with K i i = 1.9 and 13.5 nM, respectively), and further pharmacological characterization is in progress for its evaluation as a antidepressant.